Nautilus Biotechnology, Inc. announced an agreement with the Allen Institute to investigate the connection between tau protein and Alzheimer’s disease.
The Allen Institute will employ Nautilus’s proprietary Iterative Mapping, a single-molecule proteomics method, for these critical studies.
This collaboration aims to leverage next-generation proteomics technology and neuroscience leadership to potentially unlock breakthrough therapeutics and biomarkers for neurodegenerative diseases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.